Xeris Patent-Cliff Exposure & CMS Drug Spending Portfolio

Xeris (US): 2 reconciled FDA prescription therapies, $30.4M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2036-01-01
2024 CMS Total Public Spend$30.4M
2024 Medicare Part D Spend$23.5M
2024 Medicaid Spend$6.9M
California HCAI SB 17 Filings4 WAC filings (max 60.3% 2-yr change)